Honoria Guarino1, Pedro Mateu-Gelabert2, Jennifer Teubl3, Elizabeth Goodbody4. 1. Institute for Infectious Disease Research, National Development and Research Institutes (NDRI), 71 W. 23rd St., 4th Fl., New York, NY 10010, USA. Electronic address: guarino@ndri.org. 2. Institute for Infectious Disease Research, National Development and Research Institutes (NDRI), 71 W. 23rd St., 4th Fl., New York, NY 10010, USA. Electronic address: mateu-gelabert@ndri.org. 3. Institute for Infectious Disease Research, National Development and Research Institutes (NDRI), 71 W. 23rd St., 4th Fl., New York, NY 10010, USA; Sackler Institute of Graduate Biomedical Sciences, New York Langone Medical Center, 550 First Avenue, New York, NY 10016, USA. Electronic address: jrteubl@gmail.com. 4. Institute for Infectious Disease Research, National Development and Research Institutes (NDRI), 71 W. 23rd St., 4th Fl., New York, NY 10010, USA. Electronic address: goodbody@ndri.org.
Abstract
INTRODUCTION: Recent research has begun to explore the transition from nonmedical use of prescription opioids (POs) to heroin and injection drug use, adding to earlier literature identifying factors that influence the transition from intranasal to injection use of heroin. However, little research has explored how these transitions are embedded within young people's broader opioid use trajectories - individual pathways that may also include experiences of nonfatal overdose and drug treatment. METHODS: Data are from a study of 539 18-29 year-old New York City residents, recruited via Respondent-Driven Sampling, who reported past-month nonmedical use of POs and/or heroin use. Participants completed structured, computer-assisted interviews that included assessment of their ages at a series of "benchmark" events and experiences, including first use of a drug or route of administration, the onset of "regular" use of a drug (i.e., 1 or more times a week for at least 1 month), first overdose and first drug treatment. RESULTS: Results suggest a predictable, ordered pathway by which opioid use tends to progress in this cohort of young adults. Participants initiated nonmedical PO use at age 16.8, on average, and most transitioned to heroin use (83%) and heroin injection (64%), generally within 4 years of first PO misuse. Drug treatment was not typically accessed until after participants had progressed to heroin use. First overdose occurred <1 year after first heroin use, on average. CONCLUSIONS: Findings may help inform the optimal timing for delivery of primary, secondary and tertiary prevention efforts targeting young opioid users.
INTRODUCTION: Recent research has begun to explore the transition from nonmedical use of prescription opioids (POs) to heroin and injection drug use, adding to earlier literature identifying factors that influence the transition from intranasal to injection use of heroin. However, little research has explored how these transitions are embedded within young people's broader opioid use trajectories - individual pathways that may also include experiences of nonfatal overdose and drug treatment. METHODS: Data are from a study of 539 18-29 year-old New York City residents, recruited via Respondent-Driven Sampling, who reported past-month nonmedical use of POs and/or heroin use. Participants completed structured, computer-assisted interviews that included assessment of their ages at a series of "benchmark" events and experiences, including first use of a drug or route of administration, the onset of "regular" use of a drug (i.e., 1 or more times a week for at least 1 month), first overdose and first drug treatment. RESULTS: Results suggest a predictable, ordered pathway by which opioid use tends to progress in this cohort of young adults. Participants initiated nonmedical PO use at age 16.8, on average, and most transitioned to heroin use (83%) and heroin injection (64%), generally within 4 years of first PO misuse. Drug treatment was not typically accessed until after participants had progressed to heroin use. First overdose occurred <1 year after first heroin use, on average. CONCLUSIONS: Findings may help inform the optimal timing for delivery of primary, secondary and tertiary prevention efforts targeting young opioid users.
Authors: Alan Neaigus; V Anna Gyarmathy; Maureen Miller; Veronica M Frajzyngier; Samuel R Friedman; Don C Des Jarlais Journal: J Acquir Immune Defic Syndr Date: 2006-04-01 Impact factor: 3.731
Authors: Magdalena Cerdá; Julián Santaella; Brandon D L Marshall; June H Kim; Silvia S Martins Journal: J Pediatr Date: 2015-06-06 Impact factor: 4.406
Authors: Elizabeth R Stevens; Kimberly A Nucifora; Holly Hagan; Ashly E Jordan; Jennifer Uyei; Bilal Khan; Kirk Dombrowski; Don des Jarlais; R Scott Braithwaite Journal: Clin Infect Dis Date: 2020-06-10 Impact factor: 9.079
Authors: Maria L Mittal; Andrew Guise; Claudia Rafful; Patricia Gonzalez-Zuñiga; Peter Davidson; Devesh Vashishtha; Steffanie A Strathdee; Dan Werb Journal: Subst Use Misuse Date: 2019-08-07 Impact factor: 2.164